2025年1至6月份，天宇股份的营业收入构成为：仿制药原料药及中间体占比72.18%，CDMO原料药及 中间体占比16.02%，制剂占比11.43%，其他占比0.37%。 截至发稿，天宇股份市值为92亿元。 每经AI快讯，天宇股份（SZ 300702，收盘价：26.5元）11月18日晚间发布公告称，公司第五届第十七 次董事会会议于2025年11月18日在公司一楼会议室以现场结合通讯表决的方式召开。会议审议了《关于 确认董事会审计委员会成员及召集人的议案》等文件。 每经头条（nbdtoutiao）——段睿：我与蔡磊是 "找钥匙的人"，纵使生前寻不到，也要为其他渐冻症患 者铺就近路 （记者 曾健辉） ...

2025 年第一次职工代表大会决议公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为全面贯彻落实最新法律法规要求，确保浙江天宇药业股份有限公司（以下 简称"公司"）治理与监管规定保持同步，进一步规范公司运作机制，提升公司 治理水平，根据《中华人民共和国公司法》（以下简称"<公司法>"）《关于新 <公司法>配套制度规则实施相关过渡期安排》《上市公司章程指引》《深圳证券 交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》等相关法律法规、规范性文件的规定，结合公司治 理结构的调整情况，公司于 2025 年 11 月 18 日在公司一楼会议室召开了职工代 表大会，会议由公司工会主席朱国荣先生主持。 经职工代表大会认真审议，经大会会议表决，一致同意选举汪秀林先生为公 司第五届董事会职工代表董事（简历详见附件），任期自本次职工代表大会选举 通过之日起至第五届董事会任期届满之日止。 本次选举完成后，公司董事会中兼任公司高级管理人员以及由职工代表担任 的董事人数总计未超过公司董事总数 ...

证券代码：300702 证券简称：天宇股份 公告编号：2025-080 浙江天宇药业股份有限公司 2025 年第三次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 特别提示： 1.本次股东大会无新增、变更、否决提案的情况。 2.本次股东大会不涉及变更以往股东大会决议的情形。 一、会议召开和出席情况 1、会议届次：2025 年第三次临时股东大会 2、会议召集人：公司董事会 3、会议召开的日期、时间： （1）现场会议召开时间：2025 年 11 月 18 日（星期二）下午 15:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的时间为 2025 年 11 月 18 日 9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投票系统进行投 票的具体时间为 2025 年 11 月 18 日 9:15-15:00。 4、会议的召开方式：本次股东大会采取现场投票与网络投票相结合的方式。 5、会议地点：台州市黄岩江口化工开发区鑫源路 8 号公司总部大楼一楼会 议室。 6、本次会议由公 ...

浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 浙江天册律师事务所 关于 浙江天宇药业股份有限公司 2025 年第三次临时股东大会的 法律意见书 致：浙江天宇药业股份有限公司 浙江天册律师事务所（以下简称"本所"）接受浙江天宇药业股份有限公司 （以下简称"天宇股份"或"公司"）的委托，指派本所律师参加贵公司 2025 年 第三次临时股东大会，并根据《中华人民共和国证券法》（以下简称"《证券法》"）、 《中华人民共和国公司法》（以下简称"《公司法》"）和《上市公司股东会规 则》（以下简称"《股东会规则》"）等法律、法规和其他有关规范性文件的要 求出具本法律意见书。 在本法律意见书中，本所律师仅对本次股东大会表决程序及表决结果的合法 有效性发表意见，不对会议所审议的议案内容和该等议案中所表述的事实或数据 的真实性和准确性发表意见。 本法律意见书仅供天宇股份 2025 年第三次临时股东大会之目的使用。本所律 师同意将本法律意见书随天宇股份本次股东大会其他信息披露资料一并公告，并 依法对本所在其中发表的法律意见承担 ...

二、董事会会议审议情况 证券代码：300702 证券简称：天宇股份 公告编号：2025-082 浙江天宇药业股份有限公司 第五届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 浙江天宇药业股份有限公司（以下简称"公司"）第五届董事会第十七次会 议于 2025 年 11 月 18 日 16：00 在公司一楼会议室以现场结合通讯表决的方式召 开，本次会议通知于 2025 年 11 月 13 日以书面、电话、电子邮件方式送达。会 议应出席董事 8 人，实际出席人数 8 人，董事汪秀林现场参会，董事长屠勇军， 董事林洁、朱国荣、邓传亮及独立董事石锦娟、张国昀、丁寒锋均以通讯表决方 式参加会议。会议由公司董事长屠勇军先生主持，公司高级管理人员列席了本次 会议。本次董事会会议的召开符合《公司法》和《公司章程》的有关规定。 表决结果：同意：8 票；反对：0 票；弃权：0 票，获得通过。 三、备查文件 1、经与会董事签字的第五届董事会第十七次会议决议。 特此公告。 与会董事就各项议案进行了 ...

Group 1 - Tianyu Co., Ltd. experienced a stock price increase of 5.07%, reaching 27.36 CNY per share, with a trading volume of 1.01 billion CNY and a turnover rate of 1.79%, resulting in a total market capitalization of 9.521 billion CNY [1] - The company, established on February 14, 2003, and listed on September 19, 2017, is located in Taizhou, Zhejiang Province, and specializes in the production and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), formulations, and other fine chemicals, along with import and export of goods and technology [1] - The revenue composition of Tianyu Co., Ltd. includes 72.18% from generic APIs and intermediates, 16.02% from CDMO APIs and intermediates, 11.43% from formulations, and 0.36% from other supplementary products [1] Group 2 - Xiangcai Fund has a significant holding in Tianyu Co., Ltd., with its Xiangcai Medical Health Mixed A Fund (019958) increasing its stake by 20,480 shares in the third quarter, bringing the total to 273,800 shares, which accounts for 9.85% of the fund's net value, making it the second-largest holding [2] - The Xiangcai Medical Health Mixed A Fund, established on December 26, 2023, has a latest scale of 17.2816 million CNY, with a year-to-date return of 50.18%, ranking 1080 out of 8140 in its category, and a one-year return of 37.18%, ranking 1452 out of 8056 [2] - The fund manager, Zhang Quan, has been in the position for 1 year and 325 days, overseeing a total asset scale of 71.7344 million CNY, with the best fund return during his tenure being 72.41% and the worst being 71.65% [3]

Investment Rating - The report maintains a "Buy" rating for several key companies in the pharmaceutical and biotechnology sector, including WuXi AppTec, Sangamo Therapeutics, and Tigermed [2][8]. Core Insights - The report highlights a positive outlook for the pharmaceutical sector, anticipating a recovery in demand and profitability for innovative drug companies, particularly in the CRO/CDMO and life sciences upstream segments [7][14]. - The recent national medical insurance negotiations have concluded, with a focus on supporting innovative drug chains, and the new drug list is set to be implemented on January 1, 2026 [14][56]. - The report emphasizes the importance of monitoring developments in innovative therapies for breast cancer, particularly the advancements in KAT6 inhibitors and PI3K/mTOR inhibitors [15][20]. Summary by Sections Company Performance - Key companies recommended for investment include WuXi AppTec, WuXi Biologics, and Tigermed, all showing strong growth potential [2][8]. - The report notes that the pharmaceutical sector's overall market capitalization is approximately 731.50 billion, with a circulating market value of around 661.54 billion [5]. Market Trends - The report indicates that the pharmaceutical sector has experienced a decline of 2.40% recently, while the broader market (CSI 300) increased by 0.82%, suggesting a challenging environment for the sector [7][14]. - The report anticipates a gradual recovery in revenue and profit growth for the pharmaceutical sector, with a focus on innovative drugs and medical devices [14][56]. Regulatory Developments - The recent national medical insurance negotiations involved 120 companies, with 127 drugs participating in the basic medical insurance drug list negotiations [14][56]. - The introduction of a dual directory review model is expected to further support the innovative drug chain [14][56]. Innovation Focus - The report highlights the ongoing clinical trials for Celcuity's Gedatolisib and the advancements in KAT6 inhibitors by domestic companies, indicating a strong focus on innovative cancer therapies [15][20]. - The report suggests that companies like Kangchen Pharmaceutical are making significant strides in the KAT6 inhibitor space, positioning themselves competitively in the international market [53].

Core Viewpoint - Tianyu Co., Ltd. has experienced a stock price increase of 51.72% year-to-date, but has seen a slight decline in recent trading days, indicating potential volatility in the market [1][2]. Financial Performance - For the period from January to September 2025, Tianyu Co., Ltd. achieved a revenue of 2.287 billion yuan, representing a year-on-year growth of 18.36% [2]. - The net profit attributable to shareholders for the same period was 221 million yuan, showing a significant year-on-year increase of 159.57% [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for Tianyu Co., Ltd. was 15,200, a decrease of 8.06% from the previous period [2]. - The average number of circulating shares per shareholder increased by 8.76% to 13,857 shares [2]. Dividend Distribution - Since its A-share listing, Tianyu Co., Ltd. has distributed a total of 303 million yuan in dividends, with 34.8 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the fifth largest circulating shareholder, holding 6.144 million shares, an increase of 2.7532 million shares from the previous period [3].

Core Viewpoint - Tianyu Co., Ltd. is a leading domestic pharmaceutical raw material enterprise, focusing on the research and production of pharmaceutical intermediates, raw materials, and formulations, with significant technical and cost advantages [1] Financial Performance - In Q3 2025, Tianyu's revenue reached 2.287 billion yuan, ranking 8th in the industry out of 47 companies, with the industry leader, Prolo Pharmaceutical, generating 7.764 billion yuan [2] - The net profit for the same period was 221 million yuan, placing Tianyu 11th in the industry, while the top performer, Zhejiang Pharmaceutical, reported 867 million yuan [2] Profitability and Debt Ratios - As of Q3 2025, Tianyu's debt-to-asset ratio was 43.32%, down from 45.02% year-on-year, which is higher than the industry average of 27.75% [3] - The gross profit margin for the same period was 39.14%, an increase from 35.47% year-on-year, surpassing the industry average of 35.38% [3] Executive Compensation - The chairman and general manager, Tu Yongjun, received a salary of 1.688 million yuan in 2024, an increase of 670,000 yuan from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 8.06% to 15,200, while the average number of shares held per shareholder increased by 8.76% to 13,900 [5] - Hong Kong Central Clearing Limited is the fifth-largest shareholder, holding 6.144 million shares, an increase of 2.7532 million shares from the previous period [5] Business Highlights - The company has seen high growth in non-sartan products, CDMO, and formulations, with continuous improvement in profitability [5] - In H1 2025, revenue from the generic drug raw materials and intermediates business, particularly for blood sugar-lowering and anti-asthma products, grew rapidly [6] - The CDMO business benefited from expanded customer demand, while the formulation business saw improvements due to product structure optimization and marketing channel development [6]

Financial Performance - In Q3 2025, the company's revenue reached 719.55 million CNY, a year-on-year increase of 7.91% [3] - Net profit attributable to shareholders was 71.42 million CNY, up 123.90% compared to the same period last year [3] - For the first three quarters of 2025, total revenue was 2.29 billion CNY, reflecting an 18.36% growth year-on-year [3] - Net profit for the same period was 220.93 million CNY, a significant increase of 159.57% [3] Business Segments - Revenue growth in Q3 was primarily driven by the increase in formulation business, while raw materials and intermediates remained stable [3] - Non-sartan products continued to show stable growth, despite a slight decline in sartan products [3] Profitability Metrics - Overall gross margin for the first nine months of 2025 was 39.14%, an increase of 3.67 percentage points year-on-year [6] - Non-sartan raw material gross margin is on a steady upward trend due to commercialization of key products and cost optimization [6] - Sartan raw material gross margin remains stable despite competitive pricing pressures [6] Future Outlook - The formulation business is expected to enter a critical growth phase in 2026, with multiple products reaching significant sales volumes [4] - The company has set clear KPI targets for the formulation business, linking employee incentives directly to performance [4] R&D and Strategic Partnerships - R&D expenditures have been stable at around 1 billion CNY annually, with a focus on formulation development [8] - The company has established strategic partnerships with leading global pharmaceutical companies, enhancing its market position [8] - As of now, 78% of the company's raw material revenue comes from the regulated market, indicating a steady increase in scale and proportion [8]